Clinical trials: Nervous System Cancer
Brain Neoplasms, Malignant, Primary
Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System
The purpose of this crossover, single-dose, bioequivalence study is to compare the rate and extent of absorption of Temozolomide after the administration of the study product (Dralitem®, Monte Verde S.A.) and the reference…
- Trial name
- NCT02343081
- Testing
- Temozolomide
- Where
- 2 sites in Argentina
- Volunteers
- 24 people
- Sponsor
- Monte Verde SA
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
- Trial name
- NCT02003144
- Testing
- eculizumab
- Where
- 69 sites in United States, Argentina and 18 more
- Volunteers
- 119 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Glioblastoma Multiforme, Glioblastoma
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma
- Trial name
- NCT06496971
- Testing
- Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound
- Where
- 2 sites in Taiwan
- Volunteers
- 32 people
- Sponsor
- NaviFUS Corporation
Pain, Cancer
Clinical Study of KW-2246 in Patients With Cancer Pain
This study is a Phase II open-label study to investigate the recommended conversion ratio (oral morphine dose to KW-2246) when switching oral morphine or oxycodone to KW-2246 in cancer patients.
- Trial name
- NCT00355628
- Testing
- KW-2246 (fentanyl citrate)
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Glioblastoma, MGMT-Unmethylated Glioblastoma
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase…
- Trial name
- NCT03250299
- Testing
- Microtubule-Targeted Agent BAL101553, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Basilea Pharmaceutica
Solid Tumour Neoplastic Meningitis, Brain Metastases
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
The purpose of this study is to demonstrate the safety of giving Whole Brain Radiotherapy (WBRT) together with intrathecal liposomal cytarabine (DepoCyte®) for patients with leptomeningeal metastases.
- Trial name
- NCT00854867
- Testing
- Whole Brain Radio Therapy (WBRT) with sequential Depocyte, Whole brain radiotherapy (WBRT) with concomitant Depocyte
- Where
- 7 sites in Austria, Germany
- Volunteers
- 18 people
- Sponsor
- Mundipharma Research Limited
Brain and Central Nervous System Tumors
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of leflunomide in treating patients who have anaplastic…
- Trial name
- NCT00003775
- Testing
- leflunomide
- Where
- 26 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Pfizer
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of…
- Trial name
- NCT07620951
- Testing
- [14C]Zorifertinib Oral Formulation
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Malignant Glioma, Glioblastoma Multiforme
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive or recurrent malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma
- Trial name
- NCT00683761
- Testing
- 131I-TM601
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- TransMolecular
Myasthenia Gravis
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (<) 18 years of age (globally) and 8 to <18 years of age (for Unites Stated (US)…
- Trial name
- NCT05265273
- Testing
- Nipocalimab
- Where
- 19 sites in United States, Japan and 2 more
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Myasthenia Gravis
The Impact of Myasthenia Gravis in the Real World
An international, non-interventional, prospective, community recruited, longitudinal, lifestyle study which aims to collect Real-World Evidence (RWE) from people living with myasthenia gravis (MG) in order to map the disease's…
- Trial name
- NCT04176211
- Where
- United Kingdom
- Volunteers
- 2,847 people
- Sponsor
- Vitaccess Ltd
Glioblastoma Multiforme
Dendritic Cell Cancer Vaccine for High-grade Glioma
A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group receiving standard therapy with Temozolomide and…
- Trial name
- GBM-Vax (NCT01213407)
- Testing
- Trivax, Temozolomide, Surgery, Radiotherapy, Temozolomide, Surgery, Radiotherapy
- Where
- 8 sites in Austria
- Volunteers
- 87 people
- Sponsor
- Activartis Biotech
Advanced Solid Tumor, Advanced Solid Malignancies
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in…
- Trial name
- NCT05315167
- Testing
- PRJ1-3024
- Where
- 5 sites in China
- Volunteers
- 267 people
- Sponsor
- Zhuhai Yufan Biotechnologies Co., Ltd
Myasthenia Gravis, Ocular
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible…
- Trial name
- NCT07249632
- Testing
- Telitacicept
- Where
- China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Glioblastoma Multiforme
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
This study will investigate clinical activity, safety, and tolerability of the anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of glioblastoma multiforme (GBM).
- Trial name
- NCT00093964
- Testing
- Cilengitide 500 mg, Cilengitide 2000 mg
- Where
- 17 sites in United States
- Volunteers
- 81 people
- Sponsor
- EMD Serono
Central Nervous System Diseases, Central Nervous System Neoplasms
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
This is a retrospective study to collect already existing data and images from patients ≥ 2 years of age who had MRI for CNS diseases with MultiHance administration at a standard 0.10 mmol/kg dose or the half dose of 0.05…
- Trial name
- NCT03147989
- Testing
- MultiHance
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Bracco Diagnostics, Inc
Cancer, Pain
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain
- Trial name
- NCT01885182
- Testing
- Oxycodone/Naloxone, Oxycodone
- Where
- 28 sites in China
- Volunteers
- 232 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Advanced Malignant Glioma
A Phase II Study to Treat Advanced Malignant Glioma
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 for the treatment of Advanced Malignant Glioma.
- Trial name
- NCT00427440
- Testing
- AMG 102 at 20 mg/kg, AMG 102 at 10 mg/kg
- Volunteers
- 61 people
- Sponsor
- Amgen